Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aim Immunotech Inc
(NY:
AIM
)
0.2130
+0.0029 (+1.38%)
Official Closing Price
Updated: 8:00 PM EST, Nov 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aim Immunotech Inc
< Previous
1
2
3
4
5
Next >
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
January 12, 2022
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ /...
From
JTC Team, LLC
Via
AccessWire
Earnings Scheduled For November 11, 2021
November 11, 2021
Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on revenue of $465.75 million. • Reshape...
Via
Benzinga
AIM ImmunoTech Recruits hVIVO For Ampligen Trial For Prophylaxis Use Against Respiratory Viruses
September 30, 2021
AIM ImmunoTech Inc (NYSE: AIM) has signed a Clinical Trial Agreement with hVIVO for Phase 2a Human Challenge Trial (HCT) for intranasal Ampligen as prophylaxis...
Via
Benzinga
AIM ImmunoTech Plans To Evaluate Two Forms Of Ampligen In Early-COVID-19 Disease
September 28, 2021
AIM ImmunoTech Inc (NYSE: AIM) submitted a Pre-Investigational New Drug Application (Pre-IND) to the FDA for COVID-19 trials with Ampligen. The application is for two...
Via
Benzinga
Exposures
COVID-19
Product Safety
AIM ImmunoTech Receives Positive FDA Response For Ampligen Trial In PCCD Patients
September 21, 2021
AIM ImmunoTech Inc (NYSE: AIM) has announced positive progress with the FDA meeting request concerning a Phase 2 study of Ampligen for Post-COVID-19 Cognitive...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
September 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...
Via
Benzinga
Exposures
COVID-19
AIM ImmunoTech To Test Ampligen In Post-COVID-19 Cognitive Dysfunction
September 08, 2021
AIM ImmunoTech Inc (NYSE: AIM) has submitted a Pre-Investigational New Drug application (Pre-IND) to the FDA for a Phase 2 study of Ampligen as a potential...
Via
Benzinga
Exposures
Product Safety
Earnings Scheduled For August 13, 2021
August 13, 2021
Companies Reporting Before The Bell • Jaguar Health (NASDAQ:JAGX) is expected to report quarterly loss at $0.03 per share on revenue of $7.28 million. • Fangdd...
Via
Benzinga
Earnings Scheduled For May 14, 2021
May 14, 2021
Companies Reporting Before The Bell • Sogou (NYSE:SOGO) is projected to report earnings for its first quarter. • Sohu.com (NASDAQ:SOHU) is estimated to report...
Via
Benzinga
AIM ImmunoTech's Ampligen Shows Favorable Safety Profile In Early-Stage COVID-19 Study
April 07, 2021
AIM ImmunoTech Inc (NYSE: AIM) has completed the dosing of Cohort 1 in Phase 1 study on the safety of Ampligen as an intranasal therapy, as potential...
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.